title: Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
abstract: These recommendations update information regarding the polysaccharide vaccine licensed in the United States for use against disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, as well as antimicrobial agents for chemoprophylaxis against meningococcal disease (superseding MMWR 1985;34:255-9). This report provides additional information regarding meningococcal vaccines and the addition of ciprofloxacin and ceftriaxone as acceptable alternatives to rifampin for chemoprophylaxis in selected populations.
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D002443:Ceftriaxone / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000627:therapeutic use; D000075202:Contraindications; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000276:immunology*; D012293:Rifampin / Q000627:therapeutic use; D014611:Vaccination / Q000592:standards*
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D002939:Ciprofloxacin; D002443:Ceftriaxone; D012293:Rifampin